Genito-Urinary
Genito-Urinary
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
16
Clinical Trials
Genito-Urinary
Phase II
Accepting Patients
nct/study# NCT03117309 / CRN-GU16-260
Phase II Study Of Front Line Therapy With Nivolumab And Salvage Nivolumab + Ipilimumab In Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Learn More
Genito-Urinary
Phase III
Accepting Patients
nct/study# NCT04195750 / MK-6482-005
An Open-Label, Randomized Phase 3 Study Of MK-6482 Versus Everolimus In Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 And VEGF-Targeted Therapies
Learn More
Genito-Urinary
Phase III
Accepting Patients
nct/study# NCT04197986 / QBGJ398-302
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Learn More
Genito-Urinary
Phase I/II
Accepting Patients
nct/study# NCT03288545 / SGN22E-002
A Study Of Enfortumab Vedotin (ASG-22CE) As Monotherapy Or In Combination With Other Anticancer Therapies For The Treatment Of Urothelial Cancer
Learn More
Genito-Urinary
Phase III
Accepting Patients
nct/study# NCT03678025 / S1802
Phase III Randomized Trial Of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery Or Radiation) Of The Primary Tumor In Metastatic Prostate Cancer
Learn More
Genito-Urinary
Phase III
Accepting Patients
nct/study# NCT03775265 / S1806
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With Or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.